Portola Pharmaceuticals Announces Retirement of CEO Bill Lis in 2018
June 04, 2018 16:30 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that William Lis has informed the Board of Directors of his plans to...
New Interim Phase 2a Study Results Demonstrate Broad Clinical Activity of Portola Pharmaceuticals’ Oral SYK/JAK Inhibitor Cerdulatinib
June 04, 2018 08:30 ET
|
Portola Pharmaceuticals, Inc.
– Differentiated SYK-JAK Inhibitor Shows Efficacy in Patients with Heavily Pre-Treated B- and T-Cell Malignancies – – New Signal in AITL; Five Complete Responses for a Complete Response Rate of 71...
Portola Pharmaceuticals Receives $100 Million Milestone Payment from HealthCare Royalty Partners for FDA Approval of Andexxa®
May 24, 2018 08:30 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., May 24, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the company has received a $100 million milestone payment from...
Portola Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 09, 2018 16:05 ET
|
Portola Pharmaceuticals, Inc.
-- Conference Call Today at 4:30 p.m. ET -- SOUTH SAN FRANCISCO, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today reported financial results for the...
U.S. FDA Approves Portola Pharmaceuticals’ Andexxa®, First and Only Antidote for the Reversal of Factor Xa Inhibitors
May 03, 2018 21:49 ET
|
Portola Pharmaceuticals, Inc.
– Breakthrough Product is a Major Advance in the Treatment of Patients Hospitalized with Life-Threatening Bleeding – – Company to Host Conference Call on Friday, May 4, 2018 at 8:30 a.m. ET – SOUTH...
Portola Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018
April 30, 2018 16:30 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., April 30, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that it will host a webcast and conference call to discuss the Company’s...
Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
April 25, 2018 13:06 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that new interim results from the Company’s ongoing Phase 2a study of...
Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 04, 2018 08:30 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., April 04, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on March 29, 2018, the Compensation Committee of the Board of...
Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban in the European Union
March 23, 2018 09:06 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., March 23, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the...
Portola Pharmaceuticals Announces New Interim Results from Ongoing ANNEXA-4 Study of Factor Xa Inhibitor Reversal Agent AndexXa® (Andexanet Alfa) in Patients with Life-Threatening Bleeding
March 12, 2018 12:12 ET
|
Portola Pharmaceuticals, Inc.
– Excellent or Good Hemostasis Achieved in 83 Percent of Patients; Thrombotic Events Consistent with High Background Thrombotic Risk – – Data Presented in Late-Breaking Clinical Trial Session at...